GBA Presents: RADIO SAVANT-!

Goldman Sachs is cutting its market forecast for the year, but that baseline assumes no recession.

Goldman's equity strategy team cut its end-2022 target for the S&P 500 (SP500) (NYSEARCA:SPY) to 4,300from 4,700, noting investors have been "mauled" since the Jan. 3 peak for the index.

But if there is a recession, it would push the S&P down to 3,600, which would be an 11% drop from current levels.

"Our economists assign a 35% probability of recession in the next two years," strategist David Kostin wrote in a note. "However, if by year-end the economy is poised to enter a recession in 2023, a combination of reduced EPS estimates and a wider yield gap would drive a lower index level."

If the economy avoids recession, but real rates (TIP) keep rising, that would take the S&P down to 3,800.
 
Ryanair CEO blasts Boeing, calls management 'headless chickens'

Bear market rally has started, but the fall hasn't finished - Morgan Stanley

With equity "valuations now more attractive, equity markets so oversold and rates potentially stabilizing below 3%, stocks appear to have begun another material bear market rally," Morgan Stanley strategist Mike Wilson says.

"After that, weremain confident that lower prices are still ahead," Wilson wrote in a note Sunday. "In S&P 500 (SP500) (NYSEARCA:SPY) terms, we think that level is close to 3,400, which is where both valuation and technical support lie."

The bear market will last until either valuations fall to 14-15x "that discount the kind of earnings cuts we envision, or earnings estimates get cut" or earnings estimates are cut, he said.
 
This comes from a personal place.. My step father died from MM.

Sanofi (NASDAQ:SNY) said new data from a late stage study of its multiple myeloma therapy Sarclisa, in combination with other drugs, showed reducing the risk of disease getting worse by a median of nearly three years.

The phase 3 trial, dubbed IKEMA, evaluating Sarclisa (isatuximab) in combination with chemotherapy carfilzomib and corticosteroid dexamethasone (Kd) showed a median progression free survival (mPFS) of 35.7 months, compared to 19.2 months in patients treated with Kd alone.

PFS is the length of time a patient lives with the disease without it getting worse.

The study enrolled 302 patients with relapsed multiple myeloma in 69 centers spanning 16 countries.

The French drugmaker said the results showed the longest mPFS on a proteasome inhibitor backbone in patients who relapsed after a prior therapy, including lenalidomide, which sold as Revlimid by Bristol-Myers Squibb.

Sanofi added that a further analysis, following U.S. Food and Drug Administration's recommendations on censoring rules, showed mPFS increased to 41.7 months from 20.8 months with Sarclisa combo therapy.

The company said time to next treatment for patients treated with Sarclisa combo therapy was 44.9 months, compared to 25 months for those treated with Kd alone.

Sanofi said treatment emergent adverse events (TEAEs) of ≥ Grade 3 were reported in 83.6% of patients receiving Sarclisa combination therapy and in 73% of those treated with Kd alone. Serious TEAEs were higher in the Sarclisa combo arm, compared to Kd alone (70.1% versus 59.8%). No difference was seen after exposure adjustment.

The company noted that the safety of Sarclisa seen in this analysis were consistent with the safety profile of the drug in other trials, and no new safety signals were seen.

"To observe progression free survival of more than three years in patients with relapsed multiple myeloma when Sarclisa was added to a proteasome inhibitor backbone of therapy is unprecedented and reinforces our confidence in Sarclisa as a potential best in class anti-CD38 antibody," said Peter Adamson, global head of Oncology Clinical Development and Pediatric Innovation at Sanofi (SNY).
 
I like Sempra Energy Alot<------- When I am reviewing other " sexy " LNG plays often I come back to- but Sempra also does this or that.... This Co is very well placed for Europe's future needs I of course cast my bet with The Netherland's EQNR... but Sempra seems better at this point.

Sempra Energy poised to supply LNG to Poland's PGNiG
May 16, 2022 8:38 AM ET Sempra (SRE)
image_1140776266.jpg




Sempra Energy (NYSE:SRE) said on Monday it reached a heads of agreement to sell 3M metric tons/year of liquefied natural gas to Poland's PGNiG from Sempra Infrastructure's portfolio of LNG projects in North America.

Poland'slargest gas company said the agreement could lead to finalization of definitive 20-year LNG sale-and-purchase agreements for 2M tons/year from Sempra's (SRE) Cameron LNG Phase 2 project under development in Louisiana and 1M tons/year from the Port Arthur LNG project under development in Texas.

PGNiG's liquefied natural gas supply portfolio with U.S. partners currently stands at 7M tons, or 9B cm; the Sempra (SRE) contract would raise that amount by more than 40%.
 
YTD- DOWN 11%

1 month with all this nasty = +2%



YOU Clear Secure, Inc.<-- IT'S A BUY!

$28.273.39(+13.63%)12:00 PM 05/13/22
NYSE |Pre-Market:$28.82+0.55(+1.95%)4:37 AM
 
You must log in or register to reply here.
Back
Top